Main > > >LYMPHOMA. *

---

TREAT.: Acalabrutinib Capsules.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Man-
tle Cell Lymphoma (MCL)>Recurrent].
>Received One Prior Therapy.
CA Approval Date: 2019. 10.08.
USA Approval Date: 2017. 10.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.14.




TREAT.: Axicabtagene Ciloleucel Suspen-
sion for IV Infusion.
[Non Hodgkin Lymphoma (NHL)>B Cell>Di-
ffuse Large B-Cell Lymphoma (DLBCL)>
Recurrent or Refractory (R/R)].
CAR T Therapy
Cell Therapy>Gene Therapy.
EU Approval Date : 2018. 08.27.
USA Approval Date: 2017. 10.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Axicabtagene Ciloleucel Suspen-
sion for IV Infusion.
[Non Hodgkin Lymphoma (NHL)>B Cell>
Follicular Lymphoma (FL)>Recurrent/
Refractory (R/R)]
USA Approval Date: 2021. 03.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.09.




TREAT.: Axicabtagene Ciloleucel Suspen-
sion for IV Infusion.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Pri- mary Mediastinal large B-cell Lymphoma
(PMBCL)>Recurrent/Refractory (R/R)].
CAR T Therapy
Cell Therapy/Gene Therapy.
EU Approval Date: 2018. 08.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.13.




TREAT.: Belinostat for Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Peri-
pheral T-Cell Lymphoma (PTCL)>Recurrent/
Refractory (R/R].
Histone Deacetylase Inhibitor.
USA Approval Date: 2014. 07.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.14.




TREAT.: Bendamustine.HCl Inj. Brand
[Non-Hodgkin Lymphoma (NHL)>B-Cell>In-
dolent>Recurrent].
>progressed during or within six months
of treatment with rituximab or a
rituximab-containing regimen.
Mechanism: Alkylating Agent
EU Approval Date : 2010.
JP Approval Date : 2010. 10.
JP Launch Date : 2010. 12.
USA Approval Date: 2008. 11.03.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 11.04.




TREAT.: Bendamustine.HCl Inj. Generic.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>In-
dolent>Recurrent].
>progressed during or within six months
of treatment with rituximab or a
rituximab-containing regimen.
Mechanism: Alkylating Agent
USA Final Approval Date: 2017. 01.06.
(*) Company: Breckenridge Pharma.
UpDate: 2018. 11.04.




TREAT.: Bendamustine.HCl Inj. RAPID.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>In-
dolent>Recurrent].
>that has progressed during or within 6
months of treatment with rituximab or a
rituximab-containing regimen.
USA Approval Date: 2015. 12.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Bexarotene Capsules/Gel.
[Non Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)].
USA Approval Date: 1999. 12.29.
(*) Company : Bausch Health Companies
Inc.>Orho Dermatologics.
Patent : Expired.
TradeMark: Targretin.
UpDate: 2018. 11.13.




TREAT.: Bortezomib for Inj.
[Non Hodgkin Lymphoma (NHL)>B-Cell>Man-
tle Cell Lymphoma (MCL)].
Mechanism: Proteasome Inhibition.
EU Approval Date : 2015. 02.06.
>Previously UnTreated.
USA Approval Date: Since 2006.
>Recurrent/Refractive (R/R) Treat.
USA Approval Date: 2014. 10.10.
>Previously UnTreated.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Hodgkin Lymphoma (HL)>Classical].
>After Failure auto-HSCT or After Fai-
lure of at least two prior multi-agent
CT regimens in patients who are not
auto-HSCT candidates.
JP Approval Date : 2018. 09.21.
USA Approval Date: 2011. 08.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Hodgkin Lymphoma (HL)>Classical>auto-
HSCT>Recurrent].
USA Approval Date: 2015. 08.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Hodgkin Lymphoma (HL)>Classical>Stage
3/4>Previously Untreated]
+CT AVD (Adriamycin, vinblastine and dacarbazine)
EU Approval Date : 2019. 02.11.
JP Approval Date : 2018. 09.
USA Approval Date: 2018. 03.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2019. 02.12.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)>CD30+].
>One Prior Systemic Therapy
EU Approval Date: 2018. 01.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.14.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)>Relapsed
(R)].
>Received Prior Systemic Therapy.
>SubTypes>
>CD30-Expressing Mycosis Fungoides
>Primary Cutaneous Anaplastic Large
Cell Lymphoma
USA Approval Date: 2017. 11.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.13.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>sys-
temic Anaplastic Large Cell Lymphoma
(sALCL)].
Newly Diagnosed (Previously UnTreated)
+CT (Cyclophosphamide, Doxorubicin, Prednisone)
EU CE Mark Date: 2020. 05.14.
USA Approval Date: 2018. 11.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.




TREAT.: BrentuxiMAb Vedotin for Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>sys-
temic Anaplastic Large Cell Lymphoma (sALCL)>Relapsed (R)].
after failure of at least one prior multi-agent chemotherapy regimen.
USA Approval Date: 2011. 08.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.14.




TREAT.: Brexucabtagene Autoleucel Sus-
pension for IV Infusion.
(NHL>B-Cell>MCL)
CAR T Therapy
USA Approval Date: 2020. 07.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.29.




TREAT.: Chidamide Oral.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Peri-
pheral T-Cell Lymphoma (PTCL)>Recurrent/
Refractory (R/R)]
Histone De ACetylace (HDAC) Inhibitor.
Mechanism: Epigenetic Regulation.
SubTypes>
>Extranodal NK/T-Cell Lymphoma
>Vascular Immune Mother Cell Lymphoma
CN Approval Date: 2015. 01.09.
(*) Company; Patent; PR Web-Site &
TradeMark Available on Request.
UpDate: 2019. 11.25.




TREAT.: Copanlisib 60 mg Vial for Inj.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)>Recurrent].
>Received>2 Prior Systemic Treat.
Mechanism: PI3K Inhibition.
USA Approval Date: 2017. 09.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Crizotinib Capsules.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>ALK+
ALCL]
USA Approval Date: 2021. 01.14.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.21.




TREAT.: Denileukin Diftitox Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)>Recurrent].
USA Accelerated Approval: 1999.
USA Full Approval : 2008. 10.16.
(*) Company : Eisai.
Patent : Expired
TradeMark: Ontak
UpDate: 2018. 11.13.




TREAT.: Duvelisib Capsules.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Fo-
llicular Lymphoma (FL)>Recurrent/Refrac-
tory (R/R)].
>2 Prior Therapies.
USA Approval Date: 2018. 09.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Duvelisib Capsules.
[Non Hodgkin Lymphoma (NHL)>B-Cell>Small
Lymphocytic Lymphoma (SLL)>Recurrent/Re-
fractory (R/R)].
>2 Prior Therapies.
USA Approval Date: 2018. 09.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.13.




TREAT.: IbritumoMAb Tiuxetan Inj. for IV
Use.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
EU Approval Date : 2004. 01.16.
USA Approval Date: 2002. 02.19.
(*) Company : Spectrum Pharma.
Patent : Expired.
TradeMark: Zevalin.
Web-Site : www.zevalin.com/
UpDate: 2018. 11.04.




TREAT.: Ibrutinib Capsules/Tablets.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Man-
tle Cell Lymphoma (MCL)>Recurrent (R)].
>Received > 1 Prior Therapy.
USA Approval Date: 2013. 11.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.10.




TREAT.: Ibrutinib Capsules/Tablets.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Mar- ginal Zone Lymphoma (MZL)>Recurrent/Re-
fractory (R/R)].
>Requiring Systemic Therapy & received 1
prior anti-CD20-based therapy.
USA Approval Date: 2017. 01.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.10.




TREAT.: Ibrutinib Capsules/Tablets.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Wal-
denstroem s Macroglobulinemia (WM)]
USA Approval Date: 2015. 01.>
>Single Therapy
USA Approval Date: 2018. 08.27.>
>+RituxiMAb
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.10.




TREAT.: Idelalisib Tablets.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)>Recurrent].
>Worsens>Treat.>2 Prior Medicines.
Mechanism: PI3K Inhibition.
EU Approval Date : 2014. 09.18.
USA>Approval Date: 2014. 07.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Interferon Inj.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
(*) Company : Merck.
Patent : Expired.
TradeMark: Intron A.
UpDate: 2018. 11.04.




TREAT.: Iodine 131 TositumoMAb+Tositumo-
MAb.
[Non-Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)>Recurrent/Refrac-
tory (R/R)>CD20+].
USA Initial Approval: 2003.
(*) Company : GlaxoSmithKLine.
Patent : Expired.
TradeMark: Bexxar.
UpDate: 2018. 11.04.




TREAT.: Lenalidomide Capsules.
[Non Hodgkin Lymphoma (NHL)>B-Cell>Man-
tle Cell Lymphoma (MCL)>Recurrent].
>Recurrent>Treat.>2 Prior Medicines>
>1 of Which Is Bortezomib.
EU Approval Date : 2016. 07.15.
USA Approval Date: 2013. 06.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2019. 12.24.




TREAT.: Lenalidomide Capsules.+RituxiMAb
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Fo-
llicular Lymphoma (FL)>Relapsed].
Chemotherapy-Free Combination.
Grade 1-3a
EU Approval Date: 2019. 12.20.
USA Approval Date: 2019. 05.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.24.




TREAT.: Lisocabtagene Maraleucel Suspen-
sion for IV Infusion.
[Non-Hodgkin Lymphoma (NHL)>B Cell>
Diffuse Large B Cell Lymphoma (DLBCL) or
Large B Cell Lymphoma (LBCL)>R/R]
CAR T Therapy.
JP Approval Date: 2021. 03.25.
USA Approval Date: 2021. 02.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.29.




TREAT.: Mechlorethamine.HCl 0.016% Gel.
[Non-Hodgkins Lymphoma (NHL)>T-Cell>Cu-
taneous T-Cell Lymphoma (CTCL)>Mycosis
Fungoides (MF)].
Stage IA and IB who have received previous skin treatment.
Alkylating Agent.
EU Approval Date : 2017. 03.07.
USA Approval Date: 2013. 08.
USA Launch Date : 2013. 11.18.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 12.17.




TREAT.: MogamulizuMAb Inj. for IV Use.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)>Mycosis Fungoides (MF); Sézary Syndrome (SS)>
Recurrent/Refractory R/R].
USA Approval Date: 2018. 08.08.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 11.14.




TREAT.: ObinutuzuMAb Inj.+Bendamustine.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
EU Approval Date : 2016. 06.16.
USA Approval Date: 2016. 02.26.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 11.04.




TREAT.: Orelabrutinib.
Indications>
>Mantle Cell Lymphoma R/R
>Small Lymphocytic Lymphoma R/R
CN Approval Date: 2020. 12.25.
(*) Company & Patents Available on
Request.
UpDate: 2021. 02.16.




TREAT.: PembrolizuMAb Inj.
[Hodgkin Lymphoma (HL)>Classical>Recu- rrent/Refractory (R/R)].
EU Approval Date : 2017. 05.05.
USA Approval Date: 2017. 03.14.
USA Approval Date: 2020. 10.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.18.




TREAT.: PembrolizuMAb Inj.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>
PMBCL>Recurrent/Refractory (R/R)]
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.01.




TREAT.: Pixantrone.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Re-
current/Refractory (R/R)].
Aza-Anthracenedione.
EU Conditional Approval 2012.05.
(*) Company : CTI BioPharma Corp.
Patent : Expired.
TradeMark: Pixuvri
UpDate: 2018. 11.13.




TREAT.: Plerixafor Inj.+G-CSF.
[Non-Hodgkin Lymphoma (NHL)>Autologous
Transplant>Success].
CXCR4 Receptor AntAgonist.
USA Approval Date: 2008. 12.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.04.

TREAT.: PolatuzuMAb Vedotin Inj.+>
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Di-
ffuse Large B Cell Lymphoma (DLBCL)>
Relapsed or Refractory (R/R)]
+Bendamustine+RituxiMAb
>Received 2 Prior Therapies
Mechanism: CD79B Marker Inhibition
EU Approval Date: 2020. 01.21.
USA Approval Date: 2019. 06.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.22.




TREAT.: Pralatrexate Inj.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Peri-
pheral T-Cell Lymphoma (PTCL)>Recurrent/
Refractory (R/R)].
Folate Analogue Metabolic Inhibitor.
USA Approval Date: 2009. 09.24.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.14.




TREAT.: RituxiMAb. BioSimilar.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Di-
ffuse Large B-Cell Lymphoma (DLBCL)].
EU Approval Date: 2017. 06.19.
(*) Company : Novartis>Sandoz
TradeMark: Rixathon.
UpDate: 2018. 11.04.




TREAT.: RituxiMAb. BioSimilar.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
EU Approval Date: 2017. 06.19.
(*) Company : Novartis>Sandoz.
TradeMark: Rixathon
UpDate: 2018. 11.04.




TREAT.: RituxiMAb. Brand.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Di-
ffuse Large B-Cell Lymphoma (DLBCL)].
(*) Company : Roche.
Patent : Expired.
TradeMark: MabThera
UpDate: 2018. 11.04.




TREAT.: RituxiMAb. Brand.
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
(*) Company : Roche.
Patent : Expired.
TradeMark: MabThera.
UpDate: 2018. 11.04.




TREAT.: RituxiMAb+Hyaluronidase+ ..
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Di-
ffuse Large B-Cell Lymphoma (DLBCL)].
USA Approval Date: 2017. 06.22.
(*) Company : Genentech.
Licensor : Halozyme Therapeutics.
TradeMark: RITUXAN HYCELA
Web-Site :
www.gene.com/medical-
professionals/medicines/rituxan-
hycela
UpDate: 2018. 11.04.




TREAT.: RituxiMAb+Hyaluronidase+ ..
[Non Hodgkin Lymphoma (NHL)>B Cell>Fo-
llicular Lymphoma (FL)].
USA Approval Date: 2017. 06.22.
(*) Company : Genentech.
Licensor : Halozyme Therapeutics.
TradeMark: RITUXAN HYCELA
Web-Site :
www.gene.com/medical-
professionals/medicines/rituxan-
hycela
UpDate: 2018. 11.04.




TREAT.: Romidepsin for Inj. IV Use.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL) & Periphe-
ral T-Cell Lymphoma (PTCL)].
>Received>1 Prior Systemic Therapy
HDAC Inhibition
USA Approval Date: 2009. 11.05.
(*) Company : Celgene.
Patent : Expired.
TradeMark: Istodax
UpDate: 2018. 11.13.




TREAT.: Selinexor Tablets.
(NHL>B-Cell>DLBCL>R/R)
IL Approval Date: 2021. 02.04.
USA Approval Date: 2020. 06.22.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 02.16.




TREAT.: SintiliMAb Inj.>
[HODGKINs Lymphoma (HL)>Classical>Re- lapsed/Refractory (R/R)].
>2 Lines of Systemic CT.
CN Approval Date: 2018. 12.27.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.28.




TREAT.: TafasitaMAb-Cxix Inj IV Use+
Lenalidomide.
(NHL>B-Cell>DLBCL>R/R)
USA Approval Date: 2020. 07.31.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 09.27.




TREAT.: Tazemetostat Tablets>
(NHL>B-Cell>FL>R/R>EZH2 Mutation+)
>2 prior systemic therapies.
Companion Diagnostics>
>USA Approval Date: 2020. 06.19.
USA Approval Date: 2020. 06.18.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2020. 09.22.




TREAT.: Thiotepa (Alkylating Agent)+
Other ChemoTherapeutic Products as part of a High-Dose ChemoTherapy (HDCT) Consolidation Regimen Followed by Autologous Stem Cell Transplantation (ASCT).
(Central Nervous System Lymphoma).
CA Approval Date: 2017. 03.
(*) Company : Adienne.
Patent : Expired.
TradeMark: Tepadina.
Web-Site :
www.adienne.com/?page_id=1248
UpDate: 2019. 11.12.




TREAT.: TislelizuMAb.>
[Lymphoma>HL (Hodgkin Lymphoma)>Classi-
cal>Recurrent/Refractory (R/R)].
>Received > Two Prior Therapies.
Humanized IgG4 Anti-PD-1 MAb.
CN Approval Date: 2019. 12.27.
(*) Company; Patents & Web-Sites Avai-
lable on Request.
UpDate: 2019. 12.31.




TREAT.: Umbralisib Tablets>
(NHL>B Cell>FL>R/R)
>3 prior lines of systemic therapy
USA Approval Date: 2021. 02.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.




TREAT.: Umbralisib Tablets>
(NHL>B Cell>MZL R/R)
>prior anti-CD20 based regimen
USA Approval Date: 2021. 02.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.




TREAT.: Vorinostat Capsules.
[Non-Hodgkin Lymphoma (NHL)>T-Cell>Cuta-
neous T-Cell Lymphoma (CTCL)>Recurrent]
Following 2 Systemic Therapies.
HDAC Inhibition.
USA Approval Date: 2006. 10.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.13.




TREAT.: Zanubrutinib Capsules.
[Non-Hodgkin Lymphoma (NHL)>B-Cell>Man-
tle Cell Lymphoma (MCL)>Recurrent].
>Received One Prior Therapy.
USA Approval Date: 2019. 11.14.
(*) Companies; Patents; TradeMark &
Web-Sites Available on Request.
UpDate: 2019. 11.22.


>LYMPHOMA. *'s products
This section has no products